摘要
Objective: To investigate the influcnce ofchemotherapeutic agents and cytokines on growth ofbone marrow cells from MT/p210 her-ab1 transgenic mice.Methods: The bone marrow cells of transgenic chronicmyelogenous leukemia (CML) model mice carryingmetallothionein (MT) promoter/enhancer, her-abl (p210)cDNA and SV40 splicinglpoly (A) signal sequences werecultured in liquid and soft agar with hydroxyurea (Hu),5-nuorouracil (5-Fu), mouse stem cell factor (mSCF)and mouse interleukin-3 (mIL-3) independently orcollectively. The cells and colonies were counted. Thelevels of transgene expression were detected by reversetranscriptase-polymerase chain reaction (RT-PCR).Results: The cell proliferation, colony formation andtransgene expression of the bone marrow cells werestimulated with mSCF and mIL-3, but there was littlegrowth without any growth factors, or when mSCF,mIL-3 and Hu or 5-Fu were added. Conclusion: Thecombined utilization of chemotherapeutants andcytokines is a potentially effective strategy of clinicaltreatment for CML.
Objective: To investigate the influcnce ofchemotherapeutic agents and cytokines on growth ofbone marrow cells from MT/p210 her-ab1 transgenic mice.Methods: The bone marrow cells of transgenic chronicmyelogenous leukemia (CML) model mice carryingmetallothionein (MT) promoter/enhancer, her-abl (p210)cDNA and SV40 splicinglpoly (A) signal sequences werecultured in liquid and soft agar with hydroxyurea (Hu),5-nuorouracil (5-Fu), mouse stem cell factor (mSCF)and mouse interleukin-3 (mIL-3) independently orcollectively. The cells and colonies were counted. Thelevels of transgene expression were detected by reversetranscriptase-polymerase chain reaction (RT-PCR).Results: The cell proliferation, colony formation andtransgene expression of the bone marrow cells werestimulated with mSCF and mIL-3, but there was littlegrowth without any growth factors, or when mSCF,mIL-3 and Hu or 5-Fu were added. Conclusion: Thecombined utilization of chemotherapeutants andcytokines is a potentially effective strategy of clinicaltreatment for CML.
